Editorial: Is high-dose chemotherapy with autologous hematopoietic stem cell transplantation in breast cancer patients a done deal?

Women's Health

Volumn 6, Issue 4, 2010, Pages 481-485

  Cheng, Yee Chung ^a   Ueno, Naoto T ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; ISOTRETINOIN; PROGESTERONE RECEPTOR;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER RELAPSE; CANCER RESEARCH; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; EDITORIAL; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; META ANALYSIS (TOPIC); METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; BREAST TUMOR; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; MORTALITY; MULTIMODALITY CANCER THERAPY; RISK ASSESSMENT; UNITED STATES;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; RISK ASSESSMENT; TRANSPLANTATION CONDITIONING; UNITED STATES;

EID: 77954387917     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.10.31     Document Type: Editorial

References (30)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics 2009. CA Cancer J. Clin. 59 225-249 (2009)
2. Greenberg PA, Hortobagyi GN, Smith TL et al.: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J. Clin. Oncol. 14, 2197-2205 (1996). (Pubitemid 26264869)
3. Wilking N, Lidbrink E, Wiklund T et al.: Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. Ann. Oncol. 18, 694-700 (2007). (Pubitemid 46523273)
4. Hanrahan EO, Broglio K, Frye D et al.: Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years. Cancer 106, 2327-2336 (2006). (Pubitemid 43787655)
5. Roche HH, Pouillart P, Meyer N et al.: Adjuvant high-dose chemotherapy (HDC) improves early outcome for high risk (N>7) breast cancer patients: the PEGASE 01 trial. Proc. Am. Soc. Clin. Oncol. 20, abstract 102 (2001).
6. Gianni A, Bonadonna G: Updated 12-year results of a randomized clinical trial comparing standard-dose versus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with more than 3 positive nodes (LN+). Proc. Am. Soc. Clin. Oncol. 25, (Abstract 549) (2007).
7. Schrama JG, Faneyte IF, Schornagel JH et al.: Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: fnal analysis with 7 years of follow-up. Ann. Oncol. 13, 689-698 (2002).
8. Rodenhuis S, Bontenbal M, van Hoesel QGCM et al.: Effcacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann. Oncol. 17, 588-596 (2006).
9. Tallman M, Gray R, Robert N et al.: Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N. Engl. J. Med. 349, 17-26 (2003). (Pubitemid 36765099)
10. Leonard RCF, Lind M, Twelves C et al.: Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensifcation chemotherapy in high-risk breast cancer patients: a randomized trial. J. Natl Cancer Inst. 96,1076-1083 (2004). (Pubitemid 39172409)
11. Zander AR, Schmoor C, Kröger N et al.: Randomized trial of high-dose adjuvant chemotherapy with autologous haematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow up. Ann. Oncol. 19, 1082-1089 (2008). (Pubitemid 351796333)
12. Coombes RC, Howell A, Emson M et al.: High-dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial. Ann. Oncol. 16, 726-734 (2005). (Pubitemid 40767092)
13. Nitz UA, Mohrmann S, Fischer J et al.: Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre Phase III trial. Lancet 366, 1935-1944 (2005). (Pubitemid 41713983)
14. Peters W P, Rosner G, Vredenburgh J et al.: Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J. Clin. Oncol. 23, 2191-2200 (2005) (Pubitemid 46222235)
15. International Breast Cancer Study group: Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study group Trial 15-95. J. Clin. Oncol. 24, 370-378 (2006). (Pubitemid 46630455)
16. Moore HC, Green SJ, Gralow JR et al.: Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology group/Intergroup Study 9623. J. Clin. Oncol. 25, 1677-1682 (2007).
17. Tokuda Y, Tajima T, Narabayashi M et al.: Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology group, JCOG 9208. Cancer Sci. 99, 145-151 (2008). (Pubitemid 350239043)
18. Berry D, Ueno NT, Johnson MM et al.: High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 15 randomized adjuvant breast cancer trials. Breast Cancer Res. Treat. 106(Suppl. 1), S5 (2007).
19. Stadtmauer EA, O'Neill A, Goldstein LJ et al.: Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N. Engl. J. Med. 342, 1069-1076 (2000). (Pubitemid 30207689)
20. Stadtmauer EA, O'Neill L, Goldstein LJ et al.: Conventional-dose chemotherapy compared with high-dose chemotherapy (HDC) plus autologous stem cell transplantation (SCT) for metastatic breast cancer: 5-year update of the 'Philadelphia Trial' (PBT-01). Proc. Am. Soc Clin. Oncol. 21 (2002) (Abstract 43).
21. Crown J, Perey L, Lind M et al.: Superiority of tandem high-dose chemotherapy (HDC) versus optimized conventionally-dosed chemotherapy (CDC) in patients (pts) with metastatic breast cancer (MBC): the International Breast Cancer Dose Intensity Study (IBDIS 1). Proc. Am. Soc. Clin. Oncol 22 (2003) (Abstract 23).
22. Schmid P, Schippinger W, Nitsch T et al.: Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. J. Clin. Oncol. 23, 432-440 (2005). (Pubitemid 46224218)
23. Lotz JP, Cure H, Asselain B et al.: High-dose chemotherapy with haematopoieti stem cell transplantation for metastatic breast cancer patients: fnal results of the French multicentric randomised CMA/PEGASE 04 protocol. Eur. J. Cancer 41, 71-80 (2005). (Pubitemid 40036610)
24. Vredenburgh J, Coniglio D, Broadwater G et al.: Consolidation with high-dose combination alkylating agents with bone marrow transplantation signifcantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard dose chemotherapy alone. Biol. Blood Marrow Transplant 12, 195-203 (2006). (Pubitemid 43138014)
25. Vredenburgh J, Madan B, Broadwater G et al.: A randomized Phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. Bone Marrow Transplant 37, 1009-1015 (2006). (Pubitemid 43753463)
26. Biron P, Durand M, Roché H et al.: Pegase 03: a prospective randomized Phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in frst-line treatment of metastatic breast cancer. Bone Marrow Transplant 41, 555-562 (2008). (Pubitemid 351472147)
27. Crump M, Gluck S, Tu D et al.: Randomized trial of high-dose chemotherapy with autologous peripheral blood stem cell support compared with standard chemotherapy in women with metastatic breast cancer: NCIC MA.16. J. Clin. Oncol. 26, 37-43 (2008).
28. Berry D, Ueno NT, Lei X et al.: High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 6 randomized metastatic breast cancer trials. Breast Cancer Res, Treat. 107(Suppl. 1), S5
29. Cheng YC, Rondón G, Sanchez LF et al.: Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Int. J. Hematol. 90, 627-634 (2009).
30. Recchia F, Candeloro G, Necozione S et al.: Prolonged disease control after myeloablative chemotherapy, autologous transplantation and immunotherapy in high-risk early breast cancer. Anticancer Res. 30, 209-215 (2010).